ViiV to trial twice-yearly HIV antibody dosing after Phase IIb success
The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
US biochemist researching treatment of HIV and coronaviruses wins Israel's Wolf Prize
An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...
Healio2d
Two more people potentially cured of HIV
Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...
Fierce Biotech2d
Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
Giving blood linked to lower risk of pre-cancer gene
Frequent donors were more likely to have different genetic changes in their blood stem cells, scientists found.
Everyday Health5d
What Is T-Cell Lymphoma?
T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...
The Financial Express1d
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Medscape6d
AI Tool Diagnoses Multiple Diseases From One Blood Sample
By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...
ACTG Presents Four Studies at CROI Describing Findings from SLIM LIVER
SLIM LIVER was the first clinical trial to test semaglutide as a treatment for MASLD in people living with HIV. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is a common and ...